1.53
+0.035(+2.35%)
Currency In USD
Address
Times Square Tower
New York, NY 10036
United States of America
Phone
646 200 5278
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
March 12, 2008
| Name | Title | Pay | Year Born |
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, Chief Executive Officer & Director | 904,243 | 1976 |
| Dr. Dragan Cicic M.D., MBA | Senior Vice President of Clinical Development | 466,430 | 1963 |
| Mr. John Thomas Burns CPA | Senior Vice President & Chief Financial Officer | 505,158 | 1985 |
| Mr. Andrew Elnatan | Vice President and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality | 0 | N/A |
| Ms. Stacy E. Yeung | Vice President, Associate General Counsel & Head of Compliance | 0 | N/A |
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.